Cann Group Past Earnings Performance
Past criteria checks 0/6
Cann Group's earnings have been declining at an average annual rate of -24.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 47.2% per year.
Key information
-24.3%
Earnings growth rate
0.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 47.2% |
| Return on equity | -58.2% |
| Net Margin | -137.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cann Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 21 | -29 | 35 | 2 |
| 30 Sep 23 | 21 | -32 | 35 | 3 |
| 30 Jun 23 | 21 | -34 | 34 | 4 |
| 31 Mar 23 | 18 | -35 | 28 | 4 |
| 31 Dec 22 | 14 | -37 | 27 | 5 |
| 30 Sep 22 | 13 | -32 | 27 | 4 |
| 30 Jun 22 | 11 | -26 | 28 | 3 |
| 31 Mar 22 | 10 | -25 | 27 | 2 |
| 31 Dec 21 | 9 | -24 | 26 | 2 |
| 30 Sep 21 | 9 | -25 | 25 | 2 |
| 30 Jun 21 | 9 | -25 | 23 | 2 |
| 31 Mar 21 | 7 | -22 | 19 | 2 |
| 31 Dec 20 | 6 | -18 | 15 | 2 |
| 30 Sep 20 | 4 | -17 | 14 | 2 |
| 30 Jun 20 | 2 | -17 | 14 | 1 |
| 31 Mar 20 | 2 | -16 | 15 | 1 |
| 31 Dec 19 | 3 | -14 | 16 | 1 |
| 30 Sep 19 | 3 | -13 | 15 | 1 |
| 30 Jun 19 | 3 | -11 | 13 | 1 |
| 31 Mar 19 | 2 | -10 | 11 | 1 |
| 31 Dec 18 | 1 | -8 | 9 | 1 |
| 30 Sep 18 | 1 | -6 | 7 | 1 |
| 30 Jun 18 | 1 | -5 | 6 | 1 |
| 31 Mar 18 | 0 | -4 | 4 | 1 |
| 31 Dec 17 | 0 | -3 | 2 | 0 |
| 30 Sep 17 | 0 | -3 | 2 | 1 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -4 | 4 | 0 |
Quality Earnings: CNGG.F is currently unprofitable.
Growing Profit Margin: CNGG.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNGG.F is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare CNGG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNGG.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: CNGG.F has a negative Return on Equity (-58.21%), as it is currently unprofitable.